Navigation Links
Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
Date:12/7/2009

PINE BROOK, N.J., Dec. 7 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, announced today that recent animal efficacy and human safety data from the Company's Anthim® anthrax anti-toxin program were presented at the Biomedical Advanced Research and Development Authority (BARDA) Industry Day conference, December 4, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/NY01624LOGO )

In a podium presentation entitled "Advanced Development of Anthim® (ETI-204), a Highly-Effective Monoclonal Antibody for Treatment of Inhalational Anthrax: results of recent safety and efficacy studies," Dr. Leslie Casey, Vice President of Research, presented data from rabbit and primate treatment studies as well as clinical safety studies highlighting the therapeutic potential for Anthim in the treatment of anthrax disease. Using an established non-human primate treatment model, up to 79% of animals treated with a single, intravenous dose of Anthim at the onset of symptoms survived a lethal inhalational challenge with anthrax spores. All animals in this study were bacteremic at time of Anthim treatment.

The Company also reported the results of a previously conducted rabbit treatment study. A single dose of Anthim provided up to 94% survival when administered to rabbits after symptoms of disease were present. The results of these two studies are consistent with previously conducted rabbit and primate studies using Anthim and continue to show the dramatic increase in survival that Anthim can provide.

In a separate dose-escalating human clinical safety study, preliminary results show that Anthim continues to be safe and well-tolerated at doses at or above the anticipated efficacious dose in humans.

Elizabeth Posillico, PhD, President and Chief Executive Officer of Elusys, commented, "We are extremely pleased with the continued success of our Anthim program as we move into the final stages of drug development. Anthim consistently provides significant survival benefit in the treatment of anthrax infection and is safe and well-tolerated. Our drug has the potential to deliver considerable therapeutic benefit to Americans infected with anthrax in a bioterrorism emergency."

This project has been supported with federal funds from BARDA, Department of Health and Human Services (HHS), in conjunction with the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), the Department of Health and Human Services (HHS), under Contract No. HHSN272200700035C.

Anthim Background

Anthim has been extensively studied in multiple models of anthrax infection and has consistently prevented death in 70 - 100% of animals treated with a single dose of drug. Anthim shows excellent potential as an effective therapeutic for treatment of people infected or exposed to anthrax spores.

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalational anthrax following a biowarfare attack. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA. To date, Elusys has been awarded a total of $34 million in government funding for advanced development of Anthim. Funding has been received from the NIAID, BARDA, HHS, and the Department of Defense.

About Elusys

Elusys, a private company based in Pine Brook, New Jersey, is focused on the development of antibody therapeutics for the treatment of life-threatening disease. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit www.elusys.com.

SOURCE Elusys Therapeutics, Inc.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
2. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
3. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
4. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
5. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
6. Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media
7. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
8. Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
9. Dr. Brad Vince, with Vince and Associates Clinical Research, Presents at the Exploratory Development World Congress 2009
10. Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration
11. Dr. Julian Henley MD Presents BioMatrix Lift
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
Breaking Medicine News(10 mins):